UA102236C2 - Похідні еритропоетин-міметичного пептиду та їх фармацевтичні солі, їх одержання і застосування - Google Patents
Похідні еритропоетин-міметичного пептиду та їх фармацевтичні солі, їх одержання і застосуванняInfo
- Publication number
- UA102236C2 UA102236C2 UAA201007321A UAA201007321A UA102236C2 UA 102236 C2 UA102236 C2 UA 102236C2 UA A201007321 A UAA201007321 A UA A201007321A UA A201007321 A UAA201007321 A UA A201007321A UA 102236 C2 UA102236 C2 UA 102236C2
- Authority
- UA
- Ukraine
- Prior art keywords
- pharmaceutical salt
- mimetic peptide
- peptide derivatives
- preparation
- erythropoietin mimetic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Винахід належить до похідних ЕРО міметичного пептиду формули (І) R1-R2-(CH2)nl-R3-(CH2)n2-R4-R5, (I) де R1, R2, R3, R4, R5, n1, n2 є такими, як зазначено в описі винаходу, до їх фармацевтичних солей, одержання таких. Композиція включає похідні ЕРО міметичного пептиду формули (І) і їх фармацевтично прийнятні солі. Винахід також належить до застосування похідних і їх фармацевтично прийнятних солей, до застосування композиції для лікування захворювань, що характеризуються дефіцитом ЕРО, недостатньою або дефектною популяцією еритроцитів.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2007101987519A CN101456911A (zh) | 2007-12-12 | 2007-12-12 | 促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途 |
PCT/CN2008/001909 WO2009079910A1 (en) | 2007-12-12 | 2008-11-24 | An erythropoietin mimetic peptide derivatives and its pharmaceutical salt, the preparation and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
UA102236C2 true UA102236C2 (uk) | 2013-06-25 |
Family
ID=40768057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201007321A UA102236C2 (uk) | 2007-12-12 | 2008-11-24 | Похідні еритропоетин-міметичного пептиду та їх фармацевтичні солі, їх одержання і застосування |
Country Status (16)
Country | Link |
---|---|
US (1) | US8642545B2 (uk) |
EP (1) | EP2233504B1 (uk) |
JP (1) | JP5448099B2 (uk) |
KR (1) | KR101646929B1 (uk) |
CN (2) | CN101456911A (uk) |
AU (1) | AU2008341661B9 (uk) |
BR (1) | BRPI0820749B8 (uk) |
CA (1) | CA2708819C (uk) |
ES (1) | ES2541139T3 (uk) |
HK (1) | HK1136837A1 (uk) |
MX (1) | MX2010006436A (uk) |
RU (1) | RU2493168C2 (uk) |
TW (1) | TWI419706B (uk) |
UA (1) | UA102236C2 (uk) |
WO (1) | WO2009079910A1 (uk) |
ZA (1) | ZA201003998B (uk) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2709648A4 (en) * | 2011-05-19 | 2015-04-08 | Geysen Hendrik M | COMPOUNDS FOR BINDING TO THE ERYTHROPOIETIN RECEPTOR |
WO2013158871A1 (en) | 2012-04-20 | 2013-10-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of erythropoietin and derivatives for treating hypertension |
CN103450348B (zh) * | 2012-05-29 | 2016-03-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种促红细胞生成素模拟肽、其制备方法和用途 |
CN103536900B (zh) * | 2012-07-16 | 2017-06-16 | 江苏豪森药业集团有限公司 | 含有促红细胞生成素模拟肽的药物组合物 |
CN103570834A (zh) * | 2012-07-19 | 2014-02-12 | 江苏豪森药业股份有限公司 | 甲氧基聚乙二醇修饰的促红细胞生成素模拟肽衍生物 |
EP2970493B1 (en) * | 2013-03-15 | 2019-04-03 | The Board of Trustees of the Leland Stanford Junior University | Methods for achieving therapeutically effective doses of anti-cd47 agents |
CN104231039A (zh) * | 2013-06-08 | 2014-12-24 | 江苏豪森药业股份有限公司 | 用于合成促红细胞生成素模拟肽衍生物的功能小分子及其制备方法 |
CN105085653B (zh) * | 2015-08-26 | 2019-01-08 | 天津药物研究院有限公司 | 一种促红细胞生成素模拟肽及其制备方法和应用 |
CN106608912B (zh) * | 2015-10-22 | 2019-09-20 | 天津药物研究院有限公司 | 一种脂肪二羧酸偶联的epo模拟肽衍生物及其制备方法和应用 |
CN106608913B (zh) * | 2015-10-22 | 2020-05-05 | 天津药物研究院有限公司 | 一种1,2,3-丙三酸偶联的epo拟肽衍生物及其制备方法和应用 |
CN105367629B (zh) * | 2015-11-09 | 2019-01-08 | 天津药物研究院有限公司 | 一种促红细胞生成素模拟肽以及其制备方法和用途 |
CN106928338A (zh) * | 2015-12-31 | 2017-07-07 | 杭州阿德莱诺泰制药技术有限公司 | 促红细胞生成素肽及衍生物和聚合物、制备方法和应用 |
AU2017297767B2 (en) | 2016-07-12 | 2021-09-09 | Hexal Ag | Glycoprotein with reduced acetylation rate of sialic acid residues |
CN108236717A (zh) * | 2016-12-27 | 2018-07-03 | 江苏豪森药业集团有限公司 | 聚乙二醇连接臂与所修饰多肽药物的偶合物 |
KR20210060536A (ko) * | 2018-09-14 | 2021-05-26 | 에포-메드 가부시키가이샤 | 항에리트로포이에틴 수용체 펩티드 |
KR102073886B1 (ko) | 2019-05-02 | 2020-02-05 | 주식회사 미래와바다 | 잘피이식용 다공질 패널 |
CN114601916B (zh) * | 2022-04-12 | 2024-04-16 | 江苏豪森药业集团有限公司 | 一种培化西海马肽注射制剂及其制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990008822A1 (en) | 1989-02-03 | 1990-08-09 | Genetics Institute, Inc. | Erythropoietin receptor |
PL185040B1 (pl) * | 1995-06-07 | 2003-02-28 | Affymax Tech Nv | Peptyd wiążący się z receptorami erytropoetyny, kompozycja farmaceutyczna zawierająca ten peptyd i jego zastosowanie do wytwarzania środka leczniczego |
SI0964702T1 (sl) * | 1996-08-02 | 2007-02-28 | Ortho Mcneil Pharm Inc | Polipeptidi, ki imajo posamezen kovalentno vezan N-terminalni vodotopni polimer |
DK1311285T4 (en) * | 2000-05-15 | 2017-07-24 | Hoffmann La Roche | Liquid pharmaceutical composition containing an erythropoietin derivative |
CN1169827C (zh) * | 2001-08-07 | 2004-10-06 | 沈阳三生制药股份有限公司 | 一种增强多肽在体内稳定性药物的生产方法及其应用 |
EA010099B1 (ru) * | 2003-05-12 | 2008-06-30 | Афимакс, Инк. | Пептиды, которые связываются с рецептором к эритропоэтину, и способы их применения |
CA2525568C (en) * | 2003-05-12 | 2017-07-25 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
CN1820024B (zh) * | 2003-05-12 | 2011-06-22 | 阿费麦克斯公司 | 新的聚(乙二醇)修饰的化合物及其用途 |
CN100362019C (zh) * | 2004-03-02 | 2008-01-16 | 成都生物制品研究所 | 聚乙二醇修饰后具有体内生理活性的重组促红细胞生成素 |
WO2006062685A2 (en) * | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
AU2005310189A1 (en) * | 2004-11-11 | 2006-06-08 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
-
2007
- 2007-12-12 CN CNA2007101987519A patent/CN101456911A/zh active Pending
-
2008
- 2008-07-08 TW TW097125651A patent/TWI419706B/zh active
- 2008-11-24 MX MX2010006436A patent/MX2010006436A/es active IP Right Grant
- 2008-11-24 RU RU2010123466/10A patent/RU2493168C2/ru active
- 2008-11-24 WO PCT/CN2008/001909 patent/WO2009079910A1/zh active Application Filing
- 2008-11-24 UA UAA201007321A patent/UA102236C2/uk unknown
- 2008-11-24 ES ES08865748.1T patent/ES2541139T3/es active Active
- 2008-11-24 US US12/747,818 patent/US8642545B2/en active Active
- 2008-11-24 AU AU2008341661A patent/AU2008341661B9/en active Active
- 2008-11-24 KR KR1020107014960A patent/KR101646929B1/ko active IP Right Grant
- 2008-11-24 CA CA2708819A patent/CA2708819C/en active Active
- 2008-11-24 EP EP08865748.1A patent/EP2233504B1/en active Active
- 2008-11-24 CN CN2008800142471A patent/CN101675080B/zh active Active
- 2008-11-24 BR BRPI0820749A patent/BRPI0820749B8/pt active IP Right Grant
- 2008-11-24 JP JP2010537234A patent/JP5448099B2/ja not_active Expired - Fee Related
-
2010
- 2010-05-11 HK HK10104545.0A patent/HK1136837A1/xx unknown
- 2010-06-04 ZA ZA2010/03998A patent/ZA201003998B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2708819A1 (en) | 2009-07-02 |
JP5448099B2 (ja) | 2014-03-19 |
CN101456911A (zh) | 2009-06-17 |
BRPI0820749A2 (pt) | 2015-06-16 |
ZA201003998B (en) | 2011-10-26 |
CA2708819C (en) | 2018-05-15 |
WO2009079910A1 (en) | 2009-07-02 |
EP2233504A4 (en) | 2011-03-09 |
AU2008341661A1 (en) | 2009-07-02 |
RU2493168C2 (ru) | 2013-09-20 |
AU2008341661B2 (en) | 2013-08-08 |
CN101675080B (zh) | 2012-07-11 |
US20100323949A1 (en) | 2010-12-23 |
EP2233504A1 (en) | 2010-09-29 |
HK1136837A1 (en) | 2010-07-09 |
TW201002352A (en) | 2010-01-16 |
KR20110025731A (ko) | 2011-03-11 |
BRPI0820749B1 (pt) | 2020-11-24 |
JP2011506350A (ja) | 2011-03-03 |
AU2008341661B9 (en) | 2013-08-15 |
WO2009079910A8 (zh) | 2009-11-19 |
KR101646929B1 (ko) | 2016-08-09 |
TWI419706B (zh) | 2013-12-21 |
RU2010123466A (ru) | 2012-01-20 |
ES2541139T3 (es) | 2015-07-16 |
US8642545B2 (en) | 2014-02-04 |
CN101675080A (zh) | 2010-03-17 |
MX2010006436A (es) | 2010-10-06 |
BRPI0820749B8 (pt) | 2021-05-25 |
EP2233504B1 (en) | 2015-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA102236C2 (uk) | Похідні еритропоетин-міметичного пептиду та їх фармацевтичні солі, їх одержання і застосування | |
GEP20084452B (en) | Sulfonamide derivatives for the treatment of diseases | |
EA200970149A1 (ru) | Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии | |
MY143565A (en) | Novel fluorocglycoside derivatives of pyrazoles: medicaments containing these compounds, and the use thereof | |
TW200606162A (en) | Pyrazolopyridine derivatives | |
EA200870116A1 (ru) | Бициклические гетероарильные соединения | |
DE502006006107D1 (de) | Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
EA200700096A1 (ru) | Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии | |
TN2013000051A1 (en) | 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin -4-one derivatives and their use as pde9a inhibitors | |
EA200901133A1 (ru) | Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение | |
UY30472A1 (es) | Nuevos derivados de pirimidina, procesos para su preparacion composiciones farmacéuticas conteniédolos, procesos para su preparacion y aplicaciones. | |
MY147994A (en) | Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors | |
NO20071593L (no) | Pyrimidinderivater | |
UY29041A1 (es) | Derivados de amino-piperidina, su preparacion y su utilización en terapeutica | |
EA201190296A1 (ru) | Дисахариновая, дифумарово-кислая, ди-1-гидрокси-2-нафтойно-кислая и монобензойно-кислая соли 4-(диметиламино)бутил-2-(4-((2-амино-4-метил-6-(пентиламино)пиримидин-5-ил)метил)фенил)ацетата | |
DK1989174T3 (da) | Substituerede cyclohexylmethyl-derivater | |
UY29857A1 (es) | Derivados de la 4-amino-quinazolina, su preparación y su aplicación en terapéutica. | |
EA200802214A1 (ru) | 2,4-диаминопиримидины в качестве ингибиторов киназ, участвующих в регуляции клеточного цикла | |
UY29859A1 (es) | Derivados de 1-amino-isiquinolina,su preparación y su aplicación terapéutica | |
EA201100255A1 (ru) | 5-алкинилпиримидины | |
EA201070009A1 (ru) | Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии | |
UY29046A1 (es) | Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas, su preparación y su uso en terapia | |
DK1869038T3 (da) | Substituerede 5,6,7,8-tetrahydro-imidazol[1,2-a]pyridin-2-ylamin-forbindelser og deres anvendelse til fremstilling af lægemidler | |
ATE531703T1 (de) | Benzochromenderivate | |
TW200626581A (en) | Compounds, compositions containing them, preparation thereof and uses thereof |